Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Neuro-Oncology|May 12, 2016
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma modelsKader Yagiz, Tiffany T Huang, Fernando Lopez Espinoza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2014
Temozolomide does not impair gene therapy-mediated antitumor immunity in syngeneic brain tumor modelsMarianela Candolfi, Kader Yagiz, Mia Wibowo, et al.
Current Gene Therapy|October 29, 2009
Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safetyMarianela Candolfi, Kurt M Kroeger, A K M G Muhammad, et al.
Human Gene Therapy|December 9, 2017
Efficient Therapeutic Protein Expression Using Retroviral Replicating Vector with 2A Peptide in Cancer ModelsAndrew Hofacre, Kader Yagiz, Daniel Mendoza, et al.
Discovery Medicine|November 2, 2010
Gene therapy and virotherapy: novel therapeutic approaches for brain tumorsKurt M Kroeger, A K M Ghulam Muhammad, Gregory J Baker, et al.
Molecular Therapy Oncolytics|January 12, 2018
A Retroviral Replicating Vector Encoding Cytosine Deaminase and 5-FC Induces Immune Memory in Metastatic Colorectal Cancer ModelsKader Yagiz, Maria E Rodriguez-Aguirre, Fernando Lopez Espinoza, et al.
Neoplasia (New York, N.Y.)|September 7, 2012
Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeuticsMarianela Candolfi, Gwendalyn D King, Kader Yagiz, et al.
Current Gene Therapy|April 2, 2011
Gene therapy and targeted toxins for gliomaMaria G Castro, Marianela Candolfi, Kurt Kroeger, et al.
Anti-Cancer Agents in Medicinal Chemistry|June 29, 2011
Targeted toxins for glioblastoma multiforme: pre-clinical studies and clinical implementationMarianela Candolfi, Kurt M Kroeger, Weidong Xiong, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|September 22, 2012
Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer modelYohei Mineharu, A K M Ghulam Muhammad, Kader Yagiz, et al.
Pageof 3